US FDA approves Verona Pharma`s inhaled COPD therapy
Verona Pharma announces the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD in adult patients.
With a target date for FDA approval less than a month away, Sanofi and Regeneron’s megablockbuster Dupixent has gained much attention as it is on the verge of becoming the first biologic to treat chronic obstructive pulmonary disorder (COPD).
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at...
Verona Pharma plc to present additional analyses of positive Phase 3 ENHANCE studies in COPD at ATS 2024.
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company) announces that it will report its financial results for the first...
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company) announces that it will report its financial results for the fourth...
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...